Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer
Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer
Recruiting · NCT07193394 · Registry updated 2026-02-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer | Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 2 | 2026-02-23 | NCT07193394 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Eurofins | 8 |
| Institut Curie | 48 |
| Pfizer | 431 |
| UNICANCER | 111 |
9 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Centre Antoine Lacassagne | Nice | France | 2 |
| Centre Eugène Marquis | Rennes | France | 1 |
| CHU de Nîmes | Nîmes | France | 1 |
| Chu Dupuytren- Limoges | Limoges | France | 1 |
| Institut Curie_ Site Saint-Cloud | Saint-Cloud | France | 1 |
| Institut de Cancérologie de Lorraine | Vandœuvre-lès-Nancy | France | 1 |
| Institut Paoli-Calmettes | Marseille | France | 35 |
| Institut Universitaire du Cancer de Toulouse (IUCT) - Oncopole Claudius Regaud | Toulouse | France | 1 |
| Polyclinique Bordeaux Nord Aquitaine | Bordeaux | France | 1 |